ReviewCurrent oncology reports2022
Current Approaches in Hepatoblastoma-New Biological Insights to Inform Therapy.
Review in Current oncology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Hepatoblastoma: an investigation of diagnostic, prognostic, and therapeutic gene targets and biomarkers.Pediatric research · 2026Pooled it
- Quantitative analysis of tumor perfusion via contrast-enhanced ultrasound to predict the neoadjuvant chemotherapy efficacy for children with hepatoblastoma.Journal of ultrasound · 2026Article
- Trefoil Factor-3 Is a Hypoxia-Triggered Pro-Tumorigenic Factor in Hepatoblastoma.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Anlotinib mediates intrinsic drug resistance in hepatoblastoma through the GAD1/GABA pathway.Pediatric research · 2026Article
- Integrated analysis identifies CD276 in fibroblasts as a malignancy predictor and regulator of neutrophil infiltration in hepatoblastoma.Hepatology communications · 2025Article
- Derivation of Genetically Defined Murine Hepatoblastoma Cell Lines with Angiogenic Potential.Cancers · 2025Article
- Global Burden of Hepatoblastoma From 1990 to 2021 and Projection to 2030.Cancer medicine · 2025Article
- Progress in the study of therapeutic strategies for hepatoblastoma in children.World journal of gastrointestinal oncology · 2025Review
- First Transcriptome Analysis of Hepatoblastoma in Brazil: Unraveling the Pivotal Role of Noncoding RNAs and Metabolic Pathways.Biochemical genetics · 2025Article
- Development and risk stratification of a prognostic nomogram for hepatoblastoma: analysis of the SEER database.Updates in surgery · 2025Article
- Hepatoblastoma.Nature reviews. Disease primers · 2025Review
- Malignant Hepatoblast-Like Cells Sustain Stemness via IGF2-Dependent Cholesterol Accumulation in Hepatoblastoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Hepatoblastoma: From Molecular Mechanisms to Therapeutic Strategies.Current oncology (Toronto, Ont.) · 2025Review
- Global, regional, and national epidemiology of hepatoblastoma in children from 1990 to 2021: a trend analysis.Hepatology international · 2025Article
- YAP-activated NAT10 promotes hepatoblastoma progression by activating the pentose phosphate pathway.International journal of biological sciences · 2025Article
- Gamma-butyrobetaine hydroxylase (BBOX1) exerts suppressive effects on HepG2 hepatoblastoma cells.Medical oncology (Northwood, London, England) · 2024Article
- Multiphase enhanced CT-based transformer for differential diagnosis and predicting surgical risk events of solid abdominal tumors in children.Translational oncology · 2024Article
- Predicting response of hepatoblastoma primary lesions to neoadjuvant chemotherapy through contrast-enhanced computed tomography radiomics.Journal of cancer research and clinical oncology · 2024Article
- Assessment of disease control rate and safety of sorafenib in targeted therapy for advanced liver cancer.World journal of surgical oncology · 2024Article
- Sporoderm-broken spores of Ganoderma lucidum modulate hepatoblastoma malignancy by regulating RACK1-mediated autophagy and tumour immunity.Journal of cellular and molecular medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewAs the most common pediatric primary liver cancer with rising incidence, hepatoblastoma remains challenging to treat. Here, we review the current understanding of the biology of hepatoblastoma and discuss how recent advances may lead to new treatment modalities. RECENT
findingsStandard chemotherapy regimens including cisplatin, in addition to surgery, have led to high cure rates among patients with low stage hepatoblastoma; however, metastatic and relapsed disease continue to have poor outcomes. Recent genomics and functional studies in cell lines and mouse models have established a central role for the Wnt/β-catenin pathway in tumorigenesis. Targeted agents and immunotherapy approaches are emerging as potential treatment avenues. With recent gains in knowledge of the genomic and transcriptomic landscape of hepatoblastoma, new therapeutic mechanisms can now be explored to improve outcomes for metastatic and relapsed hepatoblastoma and to reduce the toxicity of current treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.